Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 4:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 3,620 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus, Adult Onset Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects

NCT01068756
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin, Rifampin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 9, 2026, 4:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effects of Puberty and Weight on Sugar Metabolism in Children

NCT01718080
View directory record Official record
Conditions
Overweight, Leanness, Adolescent
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
8 Years to 17 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Oct 9, 2026, 4:09 AM EDT
Completed Not applicable Interventional Results available

Evaluation of the Accuracy of an Implanted Glucose Sensor

NCT02647905
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Continuous Glucose Monitoring System
Device
Lead sponsor
Senseonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
9
States / cities
Concord, California • Escondido, California • Walnut Creek, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 9, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

Effects of Reiki on Painful Neuropathy and Cardiovascular Risk Factors

NCT00010751
View directory record Official record
Conditions
Coronary Disease, Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Reiki
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
20 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 9, 2026, 4:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Active You: Feasibility of a Unique Physical Activity Program to Prevent Diabetes and Heart Disease

NCT04621045
View directory record Official record
Conditions
Cardiovascular Risk Factor, Prediabetes, Overweight and Obesity, Sedentary Behavior
Interventions
The Physical Activity for The Heart (PATH) intervention, Be Active Your Way Booklet
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
40 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Beaver Falls, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 9, 2026, 4:09 AM EDT
Completed Phase 4 Interventional Results available

Effect of Exenatide on Liver and Heart Fat and Inflammation

NCT01951651
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide, Glipizide
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 9, 2026, 4:09 AM EDT
Completed Not applicable Interventional Results available

Integrating Depression Services Into DM Management

NCT01098253
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Depression
Interventions
Adherence Intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 9, 2026, 4:09 AM EDT
Completed Not applicable Interventional Results available

Vitamin D and Type 2 Diabetes Study

NCT01942694
View directory record Official record
Conditions
Prediabetes, Type 2 Diabetes
Interventions
Vitamin D (Cholecalciferol), Placebo
Dietary Supplement · Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
30 Years and older
Enrollment
2,423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Oct 9, 2026, 4:09 AM EDT
Completed Not applicable Interventional

Tablet-Aided BehavioraL Intervention EffecT on Self-management Skills

NCT02128854
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Noninsulin Dependent, Diabetes Mellitus, Type II
Interventions
Tablets Intervention
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
45 Years to 100 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 9, 2026, 4:09 AM EDT
Completed Not applicable Interventional

Acceptance and Commitment Therapy Principles for Diabetes Prevention

NCT05260983
View directory record Official record
Conditions
PreDiabetes, Diabetes Mellitus, Type 2, Diabetes, Diabetes type2
Interventions
Diabetes Prevention Education and Acceptance and Commitment Therapy, Diabetes Prevention Education Only
Behavioral
Lead sponsor
University of Oregon
Other
Eligibility
18 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 9, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus

NCT01699737
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
JTT-851, Glimepiride, Placebo for Active, Placebo for comparator
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
79
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 76 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Oct 9, 2026, 4:09 AM EDT
Enrolling by invitation Not applicable Interventional

A Community Health Worker/Pharmacist Team to Improve Blood Sugars in Diabetes Care Using Continuous Glucose Monitoring

NCT05911256
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Pharmacist Only, Continuous Glucose Monitor (CGM), Community Health Worker (CHW)
Behavioral · Device
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
25 Years to 75 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 9, 2026, 4:09 AM EDT
Terminated No phase listed Observational

G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)

NCT00255645
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
4,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
165
States / cities
Birmingham, Alabama • Columbiana, Alabama • Mobile, Alabama + 162 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2008 · Synced Oct 9, 2026, 4:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Antidiabetic Medications on the Postprandial State in Prediabetes

NCT02104739
View directory record Official record
Conditions
Prediabetes, Obesity
Interventions
Exenatide, Saxagliptin, Exenatide extended-release (ER), Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
30 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 9, 2026, 4:09 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

NCT07776509
View directory record Official record
Conditions
Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2
Interventions
Lenbelintide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
23
States / cities
Escondido, California • Lincoln, California • Walnut Creek, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 9, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

NCT01042977
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Cardiovascular Disease, Inadequate Glycaemic Control
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
45 Years and older
Enrollment
964 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
57
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2014 · Synced Oct 9, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes

NCT01045707
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/insulin aspart, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
41
States / cities
Birmingham, Alabama • Vestavia Hills, Alabama • Concord, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 9, 2026, 4:09 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Role of Microvascular Insulin Resistance and Cardiorespiratory Fitness Diabetes

NCT04791371
View directory record Official record
Conditions
Type 2 Diabetes, Overweight and Obesity
Interventions
Cardiovascular exercise
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 55 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 9, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy

NCT01163721
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
9
States / cities
Escondido, California • Los Angeles, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2013 · Synced Oct 9, 2026, 4:09 AM EDT
Completed Phase 1 Interventional Results available

Characteristics of Glargine in Type 2 Diabetics

NCT00574912
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Placebo, Insulin Glargine 0.5 u/kg body wt SC, Insulin Glargine 1.0 u/kg body wt SC, Insulin Glargine 1.5 u/kg body wt SC, Insulin Glargine 2.0 u/kg body wt SC
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 9, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

NCT00309244
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Technosphere® Insulin Inhalation Powder, 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
677 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
80
States / cities
Mobile, Alabama • Tucson, Arizona • Chula Vista, California + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 9, 2026, 4:09 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Preventing Type 2 Diabetes in Black Emergent Adult

NCT06848244
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Binge-Eating Disorder, Binge Eating, Obesity
Interventions
Appetite Awareness Training (AAT), Diabetes Prevention Program (DPP)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 9, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes

NCT00982644
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
86
States / cities
Bay Minette, Alabama • Birmingham, Alabama • Huntsville, Alabama + 80 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 9, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.

NCT00727857
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone and metformin, Pioglitazone, Metformin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
66
States / cities
Birmingham, Alabama • Haleyville, Alabama • Montgomery, Alabama + 63 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2011 · Synced Oct 9, 2026, 4:09 AM EDT